The VISIBLE Study: Understanding Comorbidities in Psoriasis Across All Skin Tones

An expert discusses how the VISIBLE study examined comorbidity burden in moderate to severe psoriasis across all skin tones, addressing disparities in research. It aimed to highlight unmet needs and improve understanding of disease impact in diverse populations.

EP: 1.Real-World Insights on Tildrakizumab

EP: 2.Tildrakizumab in Practice: Adherence and Clinical Takeaways

Now Viewing

EP: 3.The VISIBLE Study: Understanding Comorbidities in Psoriasis Across All Skin Tones

EP: 4.Comparing Biologic Treatment Patterns: Tildrakizumab vs Ustekinumab

EP: 5.Switching to Biosimilars for the Management of Psoriasis

Video content above is prompted by the following:

• What is the key background of the VISIBLE study, which examined the burden of comorbidities in participants with moderate to severe psoriasis across all skin tones?
  • What do you believe was the impetus for this study?

Related Videos